CARv3-TEAM-E T cells rapidly and dramatically shrink aggressive brain cancer

Good news! Cancer is history (soon)! Even if you don't believe in miracles, this success seems to be spectacular!

"... Just days after a single treatment, patients experienced dramatic reductions in their tumors, with one patient achieving near-complete tumor regression.  ...
“The CAR-T platform has revolutionized how we think about treating patients with cancer, but solid tumors like glioblastoma have remained challenging to treat ...
CAR-T (chimeric antigen receptor T-cell) therapy works by using a patient’s own cells to fight cancer — it is known as the most personalized way to treat the disease. A patient’s cells are extracted, modified to produce proteins on their surface called chimeric antigen receptors, and then injected back into the body to target the tumor directly. ..."

From the abstract:

"In this first-in-human, investigator-initiated, open-label study, three participants with recurrent glioblastoma were treated with CARv3-TEAM-E T cells, which are chimeric antigen receptor (CAR) T cells engineered to target the epidermal growth factor receptor (EGFR) variant III tumor-specific antigen, as well as the wild-type EGFR protein, through secretion of a T-cell–engaging antibody molecule (TEAM). Treatment with CARv3-TEAM-E T cells did not result in adverse events greater than grade 3 or dose-limiting toxic effects. Radiographic tumor regression was dramatic and rapid, occurring within days after receipt of a single intraventricular infusion, but the responses were transient in two of the three participants. ..."

‘Dramatic’ inroads against aggressive brain cancer— Harvard Gazette Cutting-edge therapy shrinks tumors in early glioblastoma trial

Preliminary Clinical Trial Results Show ‘Dramatic and Rapid’ Regression of Glioblastoma after Next Generation CAR-T Therapy

Intraventricular CARv3-TEAM-E T Cells in Recurrent Glioblastoma (no public access)

Left: MRI in Participant 3 before infusion. Right: After infusion on day five.